DBV TECHNOLOGIES EXPANDS MANAGEMENT TEAM AND MOVES TO NEW FACILITIES IN PARISI

Paris, France – 17 September 2007 – DBV Technologies (DBV), a biopharmaceutical company engaged in the development of non-invasive epicutaneous delivery technology and products, has announced today that it has expanded its management team with three major appointments. The Company has also moved to new facilities in central Paris, while maintaining its registered site in Boulogne on the outskirts of Paris. DBV is developing its proprietary, patented VIASKIN® epicutaneous delivery technology primarily for the diagnosis and treatment of allergies.

Dr. Hing Kin Chan joins DBV as Chief Business Officer from ProBioGen AG in Germany where he was Vice President of Commercial Development. In this role, Dr. Chan was responsible for securing out-licensing contracts with biotechnology companies and big pharma. Previous industry business development roles were at Eurand International S.p.A, IDEA AG, Colorcon and Lohmann Therapie Systeme. With his valuable past industry experience specifically in drug delivery, Dr. Chan will play a key role in securing partnership agreements with industry for DBV’s technologies and products.

Dr Florian Reinaud has joined DBV as its first serving Chief Financial Officer. Previously he worked at Apax Partners where he advised on and executed both venture and late stage investments in the healthcare field. Prior to this, Dr. Reinaud worked as an analyst with Schroder Salomon Smith Barney (Citigroup). As CFO, Dr. Reinaud will help secure future financings to help take DBV’s further products on to the market. Dr Reinaud holds a BA(hons) from Oxford University and a medical degree from Imperial College School of Medicine, London, UK.

Finally, Dr. Laurent Martin is welcomed to DBV as Regulatory Affairs Director. He previously worked at Orphan Europe, a company specialised in the marketing of orphan drugs where his responsibilities were divided between Regulatory Affairs and Quality Assurance. At DBV, Dr. Martin will use his international regulatory affairs experience and knowledge of the pharmaceutical industry gained at Galderma, Fournier and Guerbet to co-ordinate worldwide registration of DBV’s pharmaceutical products. Dr. Martin holds an MBA from IAE Paris Sorbonne and received his Masters in Public Health Law from the Faculty of Sceaux, France. Dr. Martin graduated as a pharmacist at the University Rene Descartes, Paris, France.

Commenting on these appointments, Jean François Biry, Chairman and CEO of DBV, said, “We are delighted that we have been able to attract three such talented and experienced new employees to the Company who will be integral to the future growth and development of DBV.”

In conjunction with these managerial appointments, DBV has also moved its operational facilities to a new and larger site near Hospital Cochin in central Paris. The Company will run all R&D operations from the new location. The new building has capacity to house 80 people, enabling DBV to expand its workforce in line with the planned expansion of its in-house R&D programs. These changes in management and location reflect DBV’s rapid growth since bringing its first product Diallertest® for cow’s milk allergy onto the market in France.

-Ends-


For more information contact:

At Northbank Communications:

Katja Stout/ Christelle Kerouedan/ Holly Griffiths
Tel: +44 (0)20 7268 3002

dbv@northbankcommunications.com

At DBV Technologies:

Jean-François Biry, Chairman and CEO
Tel: +33 (0)1 55 427878
jfbiry@dbv-technologies.com

Notes to editors:

About DBV Technologies

DBV Technologies, headquartered in Boulogne, Paris, is a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is headed by Jean-François Biry, CEO and was born out of the experience of Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV’s lead product, Diallertest® Milk, is on sale in France and several other countries for the diagnosis of cow’s milk protein allergy. The product represents a revolution for paediatrics and was awarded an International prize for Technological Innovation by the Altran foundation.

Founded in 2002, DBV Technologies has ca.30 employees and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement. More information can be found at www.dbv-technologies.com.

About VIASKIN®

The company has perfected and globally patented its VIASKIN® technology, a unique delivery system that retains the active compound on the carrier using electrostatic forces only. This allows active compounds to be presented to the epidermis of the skin without breaking the blood-skin barrier. The Company has a pipeline of Diallertest® products geared for the diagnosis of other allergies including wheat, soya bean and dust mites. The VIASKIN® technology is in development for use in treating allergies through desensitisation and for the administration of vaccines. The company is currently seeking partnerships in these areas. The technology was awarded the Siemen’s prize for Innovation 2006.